GlassScriptPhysician profile
Diane M Buchbarker
NPI 1386646719
$1,591.83
in general payments reported to CMS, 2019-2025
19 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $125 · 2021: $145 · 2022: $239 · 2023: $257 · 2024: $273 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $352.14 | 2019-2025 | Opdivo, Augtyro |
| Eisai INC. | $268.57 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $226.90 | 2019-2022 | |
| Pfizer INC. | $184.87 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $99.99 | 2023 | Imbruvica |
| Seagen INC. | $99.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $89.74 | 2024-2025 | Calquence |
| Genzyme Corporation | $53.73 | 2022-2023 | |
| Tactile Systems Technology INC | $30.00 | 2019 | |
| Genmab U.S., INC. | $27.90 | 2023 | Tivdak |
| Gilead Sciences, INC. | $25.92 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $23.93 | 2024 | Phesgo |
| Abbvie INC. | $23.62 | 2025 | |
| Kite Pharma, INC. | $19.85 | 2024 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $17.67 | 2023 | Libtayo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.57 | 2024 | |
| Array Biopharma INC | $16.23 | 2025 | Braftovi, Tukysa, Mektovi |
| Tempus Ai, INC | $14.25 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Buchbarker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.